Julie Papanek Grant is Director at Day One Biopharmaceuticals, Inc. (DAWN). They have made 10 open-market trades across 1 company since 2022, most recently 2023-03-01.
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 10 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| DAWN | 330,000 | $7.1M |
Shares reported on the most recent Form 4, priced at the 2023-03-03 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| DAWN | SELL | 2023-03-01 | 2023-03-03 | $18.61 | $465K | -4.3% | -32.8% | -30.0% |
| DAWN | SELL | 2023-02-01 | 2023-02-03 | $21.22 | $1.0M | -6.8% | -12.4% | -35.2% |
| DAWN | SELL | 2023-01-03 | 2023-01-04 | $20.65 | $1.0M | +11.8% | +0.9% | -39.7% |
| DAWN | SELL | 2022-12-08 | 2022-12-12 | $22.08 | $192K | +3.2% | +14.8% | -6.4% |
| DAWN | SELL | 2022-12-01 | 2022-12-05 | $21.67 | $320K | +1.4% | -0.8% | -13.1% |
| DAWN | SELL | 2022-11-01 | 2022-11-03 | $20.02 | $300K | +12.7% | +10.4% | +10.8% |
| DAWN | SELL | 2022-10-03 | 2022-10-05 | $20.03 | $200K | -3.7% | -5.8% | -0.9% |
| DAWN | SELL | 2022-09-21 | 2022-09-22 | $18.55 | $22.8M | +19.6% | +12.6% | +17.6% |
| DAWN | SELL | 2022-09-16 | 2022-09-20 | $20.70 | $11.0M | +2.0% | -2.0% | +0.8% |
| DAWN | SELL | 2022-09-13 | 2022-09-15 | $23.76 | $11.6M | -13.1% | -11.0% | -2.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.